Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy

Christina Pfirschke; Camilla Engblom; Steffen Rickelt; Virna Cortez‐Retamozo; Christopher Garris; Ferdinando Pucci; Takahiro Yamazaki; Vichnou Poirier-Colame; Andita Newton; Younes Redouane; Yi-Jang Lin; Gregory R. Wojtkiewicz; Yoshiko Iwamoto; Mari Mino‐Kenudson; Tiffany G. Huynh; Richard O. Hynes; Gordon J. Freeman; Guido Guido Kroemer; Laurence Zitvogel; Ralph Weissleder; Mikaël J. Pittet

Related publications

Article2016

Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy

Christina Pfirschke, Camilla Engblom, Steffen Rickelt, Virna Cortez‐Retamozo, Christopher Garris, Ferdinando Pucci, Takahiro Yamazaki, Vichnou Poirier-Colame, Andita Newton, Younes Redouane, Yi-Jang Lin, Gregory R. Wojtkiewicz, Yoshiko Iwamoto, Mari Mino‐Kenudson, Tiffany G. Huynh, Richard O. Hynes, Gordon J. Freeman, Guido Guido Kroemer, Laurence Zitvogel, Ralph Weissleder, Mikaël J. Pittet

Editorial Material2023

Immunogenic chemotherapy sensitizes RAS-mutated colorectal cancers to immune checkpoint inhibitors

Lucillia Bezu, Oliver Kepp, Guido Guido Kroemer

Article2025

Dexmedetomidine induces immunogenic cancer cell death and sensitizes tumors to PD-1 blockade

Liwei Zhao, Peng Liu, Allan Sauvat, Killian Carnet Le Provost, Jiani Liu, Andrea Checcoli, Jonathan Pol, Oliver Kepp, Guido Guido Kroemer, Lucillia Bezu

Article2017

Immune Checkpoint Blockade, Immunogenic Chemotherapy or IFN-α Blockade Boost the Local and Abscopal Effects of Oncolytic Virotherapy

Laetitia Fend, Takahiro Yamazaki, Christelle Remy, Catherine Fahrner, Murielle Gantzer, Virginie Nourtier, Xavier Préville, Éric Quéméneur, Oliver Kepp, Julien Adam, Aurélien Marabelle, Jonathan M. Pitt, Guido Guido Kroemer, Laurence Zitvogel

Editorial Material2019

Clinical evidence that immunogenic cell death sensitizes to PD-1/PD-L1 blockade

Oliver Kepp, Laurence Zitvogel, Guido Guido Kroemer

Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy

Discussion(0)

Related publications

Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy

Immunogenic chemotherapy sensitizes RAS-mutated colorectal cancers to immune checkpoint inhibitors

Dexmedetomidine induces immunogenic cancer cell death and sensitizes tumors to PD-1 blockade

Immune Checkpoint Blockade, Immunogenic Chemotherapy or IFN-α Blockade Boost the Local and Abscopal Effects of Oncolytic Virotherapy

Clinical evidence that immunogenic cell death sensitizes to PD-1/PD-L1 blockade